Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, Double-blind, Active-comparator Study of LuAA21004 in Major Depressive Disorder in Asian Countries
KCT0000432Phase 3Recruiting
- Sponsor
- Lundbeck
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vortioxetine in major depressive disorder (MDD) (2 arms), sponsored by Lundbeck. Started May 2012; status: recruiting.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on KCT0000432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000432.